Skip to content
← Full study record

NCT02224781 · OUTCOME

3-year OS

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma · Source last updated 2026-08-28

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry

What was measured

Overall Survival (OS) was defined as the time from randomization to death from any cause. Patients who have not died would be censored at the date of last known alive. 3-year OS rate was defined as a proportion of patients who are alive after three years of follow-up time among all cases who have died within 3 years or alive after 3-year follow-up time. Kaplan-Meier method was used to estimate 3-year OS.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
Overall Survival (OS) was defined as the time from randomization to death from any cause. Patients who have not died would be censored at the date of last known alive. 3-year OS rate was defined as a proportion of patients who are alive after three years of follow-up time among all cases who have died within 3 years or alive after 3-year follow-up time. Kaplan-Meier method was used to estimate 3-year OS.
reporting Status
NOT_POSTED
time Frame
assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry
title
3-year OS
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice